Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury

Jan Xu, Gyeong Moon Kim, S. Hinan Ahmed, Jinming Xu, Ping Yan, Xiao-Ming Xu, Chung Y. Hsu

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Post-traumatic inflammatory reaction may contribute to progressive tissue damage after spinal cord injury (SCI). Two key transcription factors, nuclear factor κB (NF-κB) and activator protein-1 (AP-1), are activated in inflammation. An increase in NF-κB binding activity has been shown in the injured spinal cord. We report activation of AP-1 after SCI. Electrophoretic mobility shift assay showed that AP-1 binding activity increased after SCI, starting at 1 hr, peaking at 8 hr, and declining to basal levels by 7 d. Methylprednisolone (MP) is the only therapeutic agent approved by the Food and Drug Administration for treating patients with acute traumatic SCI. MP reduced post-traumatic AP-1 activation. RU486, a glucocorticoid receptor (GR) antagonist, reversed MP inhibition of AP-1 activation. Immunostaining showed an increase in the expression of the Fos-B and c-Jun components of AP-1 in the injured cord. A c-fos antisense oligodeoxynucleotide (ODN) inhibited AP-1, but not NF-κB, activation after SCI. AP-1 and NF-κB can transactivate genes encoding matrix metalloproteinase-1 (MMP-1) and MMP-9. Western blotting and immunostaining show increased expression of MMP-1 and MMP-9 in the injured cord. MP inhibited MMP-1 and MMP-9 expression after SCI. RU486 reversed this MP effect. The c-fos antisense ODN, however, failed to suppress MMP-1 or MMP-9 expression. These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-κB transcription cascades via a GR mechanism. Expression of inflammatory genes such as MMP-1 and MMP-9 that are transactivated jointly by AP-1 and NF-κB may not be suppressed by inhibiting only AP-1 activity.

Original languageEnglish (US)
Pages (from-to)92-97
Number of pages6
JournalJournal of Neuroscience
Volume21
Issue number1
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Glucocorticoid Receptors
Transcription Factor AP-1
Matrix Metalloproteinases
Spinal Cord Injuries
Methylprednisolone
Matrix Metalloproteinase 1
Oligodeoxyribonucleotides
Electrophoretic Mobility Shift Assay
United States Food and Drug Administration
Protein Binding
Spinal Cord
Transcription Factors
Western Blotting
Inflammation
Gene Expression

Keywords

  • Inflammation
  • Methylprednisolone
  • NF-κB
  • Protease
  • RU486
  • Transc ription factor

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. / Xu, Jan; Kim, Gyeong Moon; Ahmed, S. Hinan; Xu, Jinming; Yan, Ping; Xu, Xiao-Ming; Hsu, Chung Y.

In: Journal of Neuroscience, Vol. 21, No. 1, 01.01.2001, p. 92-97.

Research output: Contribution to journalArticle

Xu, Jan ; Kim, Gyeong Moon ; Ahmed, S. Hinan ; Xu, Jinming ; Yan, Ping ; Xu, Xiao-Ming ; Hsu, Chung Y. / Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. In: Journal of Neuroscience. 2001 ; Vol. 21, No. 1. pp. 92-97.
@article{1c2acc4c014b407f84638b1e02ab04e3,
title = "Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury",
abstract = "Post-traumatic inflammatory reaction may contribute to progressive tissue damage after spinal cord injury (SCI). Two key transcription factors, nuclear factor κB (NF-κB) and activator protein-1 (AP-1), are activated in inflammation. An increase in NF-κB binding activity has been shown in the injured spinal cord. We report activation of AP-1 after SCI. Electrophoretic mobility shift assay showed that AP-1 binding activity increased after SCI, starting at 1 hr, peaking at 8 hr, and declining to basal levels by 7 d. Methylprednisolone (MP) is the only therapeutic agent approved by the Food and Drug Administration for treating patients with acute traumatic SCI. MP reduced post-traumatic AP-1 activation. RU486, a glucocorticoid receptor (GR) antagonist, reversed MP inhibition of AP-1 activation. Immunostaining showed an increase in the expression of the Fos-B and c-Jun components of AP-1 in the injured cord. A c-fos antisense oligodeoxynucleotide (ODN) inhibited AP-1, but not NF-κB, activation after SCI. AP-1 and NF-κB can transactivate genes encoding matrix metalloproteinase-1 (MMP-1) and MMP-9. Western blotting and immunostaining show increased expression of MMP-1 and MMP-9 in the injured cord. MP inhibited MMP-1 and MMP-9 expression after SCI. RU486 reversed this MP effect. The c-fos antisense ODN, however, failed to suppress MMP-1 or MMP-9 expression. These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-κB transcription cascades via a GR mechanism. Expression of inflammatory genes such as MMP-1 and MMP-9 that are transactivated jointly by AP-1 and NF-κB may not be suppressed by inhibiting only AP-1 activity.",
keywords = "Inflammation, Methylprednisolone, NF-κB, Protease, RU486, Transc ription factor",
author = "Jan Xu and Kim, {Gyeong Moon} and Ahmed, {S. Hinan} and Jinming Xu and Ping Yan and Xiao-Ming Xu and Hsu, {Chung Y.}",
year = "2001",
month = "1",
day = "1",
language = "English (US)",
volume = "21",
pages = "92--97",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "1",

}

TY - JOUR

T1 - Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury

AU - Xu, Jan

AU - Kim, Gyeong Moon

AU - Ahmed, S. Hinan

AU - Xu, Jinming

AU - Yan, Ping

AU - Xu, Xiao-Ming

AU - Hsu, Chung Y.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Post-traumatic inflammatory reaction may contribute to progressive tissue damage after spinal cord injury (SCI). Two key transcription factors, nuclear factor κB (NF-κB) and activator protein-1 (AP-1), are activated in inflammation. An increase in NF-κB binding activity has been shown in the injured spinal cord. We report activation of AP-1 after SCI. Electrophoretic mobility shift assay showed that AP-1 binding activity increased after SCI, starting at 1 hr, peaking at 8 hr, and declining to basal levels by 7 d. Methylprednisolone (MP) is the only therapeutic agent approved by the Food and Drug Administration for treating patients with acute traumatic SCI. MP reduced post-traumatic AP-1 activation. RU486, a glucocorticoid receptor (GR) antagonist, reversed MP inhibition of AP-1 activation. Immunostaining showed an increase in the expression of the Fos-B and c-Jun components of AP-1 in the injured cord. A c-fos antisense oligodeoxynucleotide (ODN) inhibited AP-1, but not NF-κB, activation after SCI. AP-1 and NF-κB can transactivate genes encoding matrix metalloproteinase-1 (MMP-1) and MMP-9. Western blotting and immunostaining show increased expression of MMP-1 and MMP-9 in the injured cord. MP inhibited MMP-1 and MMP-9 expression after SCI. RU486 reversed this MP effect. The c-fos antisense ODN, however, failed to suppress MMP-1 or MMP-9 expression. These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-κB transcription cascades via a GR mechanism. Expression of inflammatory genes such as MMP-1 and MMP-9 that are transactivated jointly by AP-1 and NF-κB may not be suppressed by inhibiting only AP-1 activity.

AB - Post-traumatic inflammatory reaction may contribute to progressive tissue damage after spinal cord injury (SCI). Two key transcription factors, nuclear factor κB (NF-κB) and activator protein-1 (AP-1), are activated in inflammation. An increase in NF-κB binding activity has been shown in the injured spinal cord. We report activation of AP-1 after SCI. Electrophoretic mobility shift assay showed that AP-1 binding activity increased after SCI, starting at 1 hr, peaking at 8 hr, and declining to basal levels by 7 d. Methylprednisolone (MP) is the only therapeutic agent approved by the Food and Drug Administration for treating patients with acute traumatic SCI. MP reduced post-traumatic AP-1 activation. RU486, a glucocorticoid receptor (GR) antagonist, reversed MP inhibition of AP-1 activation. Immunostaining showed an increase in the expression of the Fos-B and c-Jun components of AP-1 in the injured cord. A c-fos antisense oligodeoxynucleotide (ODN) inhibited AP-1, but not NF-κB, activation after SCI. AP-1 and NF-κB can transactivate genes encoding matrix metalloproteinase-1 (MMP-1) and MMP-9. Western blotting and immunostaining show increased expression of MMP-1 and MMP-9 in the injured cord. MP inhibited MMP-1 and MMP-9 expression after SCI. RU486 reversed this MP effect. The c-fos antisense ODN, however, failed to suppress MMP-1 or MMP-9 expression. These findings demonstrate that MP may suppress post-traumatic inflammatory reaction by inhibiting both the AP-1 and NF-κB transcription cascades via a GR mechanism. Expression of inflammatory genes such as MMP-1 and MMP-9 that are transactivated jointly by AP-1 and NF-κB may not be suppressed by inhibiting only AP-1 activity.

KW - Inflammation

KW - Methylprednisolone

KW - NF-κB

KW - Protease

KW - RU486

KW - Transc ription factor

UR - http://www.scopus.com/inward/record.url?scp=0035144802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035144802&partnerID=8YFLogxK

M3 - Article

C2 - 11150324

AN - SCOPUS:0035144802

VL - 21

SP - 92

EP - 97

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 1

ER -